# Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS

> **NCT07498634** · PHASE3 · COMPLETED · sponsor: **Zhejiang Kanova Biopharmaceutical Co., LTD** · enrollment: 323 (actual)

## Conditions studied

- Phase III

## Interventions

- **DRUG:** XKH004
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07498634
- **Lead sponsor:** Zhejiang Kanova Biopharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-21
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-11-14
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498634, "Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07498634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*